Table 1 Patients characteristics and pretreatment

From: Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: Results of a prospectively randomised Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN)

 

Treatment

Characteristics

Arm Aa (n)

Arm Ba (n)

All patients ( n)

Entered

135

68

203

Age (years)

   

 Median

59

60

59

 Range

31–77

38–77

31–77

Sex

   

 Male

97

54

151

 Female

38

14

52

Radical nephrectomy

135

68

203

Stratum

   

 pT3b/c pN0 or T4pN0

50

27

77

 pN+

28

8

36

 R0

57

33

90

Local

9

4

13

Lymph nodes

5

5

10

Organ metastases

37

22

59

Site unknown

6

2

8

Histological subtype

   

 Clear cell

84

41

125

 Granular

3

2

5

 Sarkomatoid

2

1

3

 Papillary

1

1

2

 Mixed

22

8

30

 Unknown

23

15

38

Systemic pretreatment

   

 Chemotherapy

0

1

1

 Immunotherapyb

4

6

10

 Naturopathic therapy

1

0

1

 Unknown

6

0

6

  1. aArm A (8 weeks of sc-rIL-2/sc-rIFN-α /iv 5-FU); Arm B (observation).
  2. bIncluding IL-2/IFN-α2, IL-2/Vaccine, and Vaccine.
  3. sc-rIL-2=subcutaneous interleukin-2; sc-rIFN-α2=subcutaneous interferon-alpha2a, and iv-5-FU=intravenous 5-fluorouracil.
Back to article page